The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands

Pharmacology and Therapeutics

Volumn 82, Issue 2-3, 1999, Pages 251-261

  Marquez, Victor E ^a   Nacro, Kassoum ^a   Benzaria, Samira ^a   Lee, Jeewoo ^a   Sharma, Ravij ^a   Teng, Kelly ^a   Milne, George W A ^a   Bienfait, Bruno ^a   Wang, Shaomeng ^a   Lewin, Nancy E ^b   Blumberg, Peter M ^b  

^a Laboratory of Medicinal Chemistry   (United States)

^b Lab Cell Carcinogenesis Tum Prom   (United States)

Author keywords

Diacylglycerol; Diacylglycerol lactones; PKC activation; PKC binding; PKC isozymes; Protein kinase C (PKC)

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; DIACYLGLYCEROL; DIACYLGLYCEROL DERIVATIVE; DIACYLGLYCEROL LACTONE; HETEROCYCLIC COMPOUND; ISOENZYME; LACTONE DERIVATIVE; PHORBOL ESTER; PROTEIN KINASE C; RECEPTOR; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CONFERENCE PAPER; DRUG CONFORMATION; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HYDROPHOBICITY; LIGAND BINDING; LIPOPHILICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DOMAIN; X RAY ANALYSIS;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; FORECASTING; HUMANS; ISOENZYMES; LIGANDS; NEOPLASMS; PHARMACOLOGY; PROTEIN KINASE C; PROTEIN KINASES;

EID: 0032986851     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00048-5     Document Type: Conference Paper

References (54)

1. Benzaria S., Bienfait B., Nacro K., Wang S., Lewin N.E., Beheshti M., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol (DAG). The indispensable role of the sn-1 and sn-2 carbonyls in the binding of DAG-lactones to protein kinase C (PK-C). Bioorg. Med. Chem. Lett. 8:1998;3403-3408.
2. Berridge M.J. Inositol triphosphate and diacylglycerol as second messengers. Biochem. J. 220:1984;345-360.
3. Boyd M.R., Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34:1995;91-109.
4. Caloca M.J., Fernandez N., Lewin N.E., Ching D.X., Modali R., Blumberg P.M., Kazanietz M.G. Beta 2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters. J. Biol. Chem. 272:1997;26488-26496.
5. Ebinu J.O., Bottorff D.A., Chan E.Y.W., Stang S.L., Dunn R.J., Stone J.C. RasGRP, a Ras guanyl nucleotide-releasing protein with calcium and diacylglycerol binding motifs. Science. 280:1998;1082-1086.
6. Ganong B.R., Loomis C.R., Hannun Y.A., Bell R. Specificity and mechanism of protein kinase C activation by sn-1,2-diacylglycerols. Proc. Natl. Acad. Sci. USA. 83:1986;1184-1188.
7. Gulakowski R.J., McMahon J.B., Buckheit R.W., Gustafson K.R., Boyd M.R. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res. 33:1997;87-97.
8. Han Z.T., Zhu X.X., Yang R.Y., Sun Y.J., Tian G.F., Liu X.J., Cao G.S., Newmark H.L., Conney A.H., Chang R.L. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia. preliminary studies on therapeutic efficacy and toxicity Proc. Natl. Acad. Sci. USA. 95:1998;5357-5361.
9. Hodgkin M.N., Pettitt T.R., Martin A., Michell R.H., Pemberton A.J., Wakelam M.J.O. Diacylglycerols and phosphatidates. which molecular species are intracellular messengers? Trends Biochem. Sci. 23:1998;200-204.
10. Hommel U., Zurini M., Luyten M. Solution structure of a cysteine rich domain of rat protein kinase C. Nature Struct. Biol. 1:1994;383-387.
11. Ichikawa S., Hatanaka H., Takeuchi Y., Ohno S., Inagaki F. Solution structure of cysteine-rich domain of protein kinase C alpha. J. Biochem. 117:1995;566-574.
12. Jayson G.C., Crowther D., Prendiville J., McGown A.T., Scheid C., Stern P., Young R., Brenchley P., Chang J., Owens S., Pettit G.R. A phase I trial of bryostatin-1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer. 72:1995;461-468.
13. Kazanietz M.G., Krausz K.W., Blumberg P.M. Differential irreversible insertion of protein kinase C into phospholipid vesicles by phorbol esters and related activators. J. Biol. Chem. 267:1992;20878-20886.
14. Kerr D.E., Kissinger L., and Shoyab F. Cyclohexane diester analogues of phorbol ester as potential activators of protein kinase-C. J. Med. Chem. 33:1990;1958-1962.
15. Kong F., Kishi Y., Perez-Sala D., Rando R.R. The pharmacophore of debromoaplysiatoxin responsible for protein kinase C activation. Proc. Natl. Acad. Sci. USA. 88:1991;1973-1976.
16. Krauter G., VonderLieth C.W., Schmidt R., Hecker E. Structure/activity relationships of polyfunctional diterpenes of the tigliane type - A pharmacophore model for protein-kinase-C activators based on structure/activity studies and molecular modeling of the tumor promoters 12-O-tetradecanoylphorbol 13-acetate and 3-O-tetradecanoylingenol. Eur. J. Biochem. 242:1996;417-427.
17. Laughton C.A., Dale I.L., Gescher A. Studies on bioactive compounds. Synthesis and lack of growth-inhibitory properties of cyclohexane-1,2,4-triol 1,2-diesters, which resemble ring C of the phorbol ester molecule. J. Med. Chem. 32:1989;428-433.
18. Lee J., Teng K., Marquez V.E. Synthesis of two rigid diacylglycerol analogues having a bis-butyrolactone skeleton. Tetrahedron Lett. 33:1992;1539-1542.
19. Lee J., Marquez V.E., Bahador A., Kazanietz M.G., Blumberg P.M. Synthesis of two rigid diacylglycerol analogues having a perhydro furo[3,2-b]furan bis-γ-butyrolactone skeleton. Tetrahedron Lett. 34:1993;4317-4320. a.
20. Lee J., Marquez V.E., Blumberg P.M., Krausz K.W., Kazanietz M.G. Conformationally constrained analogues of diacylglycerol (DAG). Differential interaction of δ-lactones and γ-lactones with protein kinase C (PK-C). Bioorg. Med. Chem. 1:1993;119-123. b.
21. Lee J., Marquez V.E., Lewin N.E., Bahador A., Kazanietz M.G., Blumberg P.M. Conformationally constrained analogues of diacylglycerol (DAG). Interactions of α-alkylidene-γ-lactones with protein kinase C (PK-C). Bioorg. Med. Chem. Lett. 3:1993;1107-1110. c.
22. Lee J., Marquez V.E., Lewin N.E., Blumberg P.M. Synthesis of two rigid diacylglycerol analogues having a perhydro furo[3,4-b]furan bis-γ-butyrolactone skeleton. Tetrahedron Lett. 34:1993;4313-4316. d.
23. Lee J., Marquez V.E., Lewin N.E., Kazanietz M.G., Bahador A., Blumberg P.M. Conformationally constrained analogues of diacylglycerol (DAG). Interactions of α-alkyl-γ-lactones with protein kinase C (PK-C). Bioorg. Med. Chem. Lett. 3:1993;1101-1106. e.
24. Lee J., Lewin N.E., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol. The effect of side-chain orientation on the protein kinase C (PK-C) binding affinity of δ-lactones. Bioorg. Med. Chem. Lett. 4:1994;2405-2410. a.
25. Lee J., Marquez V.E., Lewin N.E., Blumberg P.M. Conformationally constrained analogues of diacylglycerol. Interaction of a medium-size ε-lactone with protein kinase C (PK-C). Bioorg. Med. Chem. Lett. 4:1994;543-548. b.
26. Lee, J., Marquez, V. E., Lewin, N. E. and Blumberg, P. M. (1994c) Synthesis of two rigid diacylglycerol analogues having a 1,7-dioxaspiro[4.4]nonane bis-γ-butyrolactone skeleton. Synlett 206-208.
27. Lee J., Sharma R., Teng K., Lewin N.E., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of DAG. Changes in PK-C binding affinity produced by isosteric groups of the 3-O-acyl function in 2-deoxy-L-ribonolactones. Bioorg. Med. Chem. Lett. 4:1994;1369-1374. d.
28. Lee, J., Wang, S., Barchi, J. J., Jr. and Marquez, V. E. (1995) Synthesis of a rigid diacylglycerol analogue having a bis-g-butyrolactone skeleton separated by a cyclopentane ring. Chem. Lett. 299-300.
29. Lee J., Lewin N.E., Acs P., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol. Protein kinase C ligands based on templates derived from 2,3-dideoxy-L-erythro(threo)-hexono-1,4-lactone and 2-deoxyapiolactone. J. Med. Chem. 39:1996;4912-4919. a.
30. Lee J., Lewin N.E., Blumberg P.M., Marquez V.E. Synthesis of bis-γ-butyrolactones containing conformationally constrained (S)- and (R)-diacylglycerol structures. Bioorg. Med. Chem. Lett. 4:1996;1299-1305. b.
31. Lee J., Sharma R., Wang S., Milne G.W.A., Lewin N.E., Szallazi Z., Blumberg P.M., George C., Marquez V.E. Conformationally constrained analogues of diacylglycerol. Ultrapotent protein kinase C (PK-C) ligands based on a chiral 4-disubstituted heptono-1,4-lactone template. J. Med. Chem. 39:1996;36-45. c.
32. Lee J., Wang S., Milne G.W.A., Sharma R., Lewin N.E., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol. Ultrapotent protein kinase C (PK-C) ligands based on a chiral 5-disubstituted tetrahydro-2-furanone template. J. Med. Chem. 39:1996;29-35. d.
33. Lee J., Jeong S.H., Chun M.W., Lewin N.E., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol. protein kinase C (PK-C) ligands based on a 5-disubstituted tetrahydro-2-furanone having an (R)-hydroxyethyl group Carbohydr. Lett. 2:1997;307-312.
34. Lee J., Lewin N.E., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol having a perhydrofuro[3,4-c]furan-1,4-dione bis-γ-butyrolactone skeleton. Arch. Pharmacol. Res. 21:1998;164-167.
35. Marquez V.E., Lee J., Sharma R., Teng K., Wang S., Bahador A., Kazanietz M.G., Lewin N.E., Blumberg P.M. Conformationally constrained analogues of diacylglycerol. Changes in PK-C binding affinity for 3-O-acyl-2-deoxy-L-ribonolactones bearing different acyl chains. Bioorg. Med. Chem. Lett. 4:1994;355-360.
36. Marquez V.E., Sharma R., Wang S., Lewin N.E., Blumberg P.M., Kim I.-S., Lee J. Conformationally constrained analogues of diacylglycerol (DAG). Dissection of the roles of the sn-1 and sn-2 carbonyls in DAG mimetics by isopharmacophore replacement. Bioorg. Med. Chem. Lett. 8:1998;1757-1762.
37. Molleyres L.P., Rando R.R. Structural studies on the diglyceride-mediated activation of kinase C. J. Biol. Chem. 263:1988;14832-14838.
38. Morimoto, Y., Mikami, A. and Shirahama, H. (1991) Unprecedented stability of δ-lactones with axial substituents rather than equatorial ones; comparison with the Prelog-Djerassi lactone derivative. J. Chem. Soc. Chem. Commun. 1376-1378.
39. Morris, G. M., Goodsell, D. S., Huey, R. and Olson, A. J. (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput.-Aided Mol. Des. 10: 293-304. URL of AutoDock: http://www.scripps.edu/pub/olson-web/doc/autodoc/index.html.
40. Nakamura H., Kishi Y., Pajares M.A., Rando R.R. Structural basis of protein kinase-C activation by tumor promoters. Proc. Natl. Acad. Sci. USA. 86:1989;9672-9676.
41. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase-C. Science. 258:1992;607-614.
42. Ono Y., Fujii T., Igarashi K., Kuno T., Tanaka C., Kikkawa U., Nishizuka Y. Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. Proc. Natl. Acad. Sci. USA. 86:1989;4868-4871.
43. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines. development of the mean graph and COMPARE algorithm J. Natl. Cancer Inst. 81:1989;1088-1092.
44. Prendiville J., Crowther D., Thatcher N., Woll P.J., Fox B.W., McGown A., Testa N., Stern P., McDermott R., Potter M., Pettit G.R. A phase-I study of intravenous bryostatin-1 in patients with advanced cancer. Br. J. Cancer. 68:1993;418-424.
45. Rando R.R. Regulation of protein kinase activity by lipids. FASEB J. 2:1988;2348-2355.
46. Rando R.R., Young N. The stereospecific activation of protein kinase C. Biochem. Biophys. Res. Commun. 122:1984;818-823.
47. Sharkey N.A., Blumberg P.M. Comparison of the activity of phorbol-12-myristate-13-acetate and the diglyceride glycerol-1-myristate-2-acetate. Carcinogenesis. 7:1986;677-679.
48. Sharma R., Marquez V.E., Milne G.W.A., Lewin N.E., Blumberg P.M. Conformationally constrained analogues of diacylglycerol. 2,5-Dideoxy-3-O-tetradecanoyl-D-galactono-1,4-lactone. a superior homologue of 3-O-tetradecanoyl-2-deoxy-L-ribonolactone with PK-C binding affinity Bioorg. Med. Chem. Lett. 3:1993;1993-1998.
49. Sharma R., Lee J., Wang S., Milne G.W.A., Lewin N.E., Blumberg P.M., Marquez V.E. Conformationally constrained analogues of diacylglycerol. Ultrapotent protein kinase C (PK-C) ligands based on a racemic 5-disubstituted tetrahydro-2-furanone template. J. Med. Chem. 39:1996;19-28.
50. Shukla S.D., Halenda S.P. Phospholipase D in cell signalling and its relationship to phospholipase C. Life Sci. 48:1991;851-866.
51. Teng K., Marquez V.E., Milne G.W., Barchi J.J. Jr., Kazanietz M.G., Lewin N.E., Blumberg P.M., Abushanab E. Conformationally constrained analogues of diacylglycerol. Interaction of γ-lactones with the phorbol ester receptor of protein kinase C. J. Am. Chem. Soc. 114:1992;1059-1070.
52. Wang S., Milne G.W.A., Nicklaus M.C., Marquez V.E., Lee J., Blumberg P.M. Protein kinase C. Modeling of the binding site and prediction of binding constants. J. Med. Chem. 37:1994;1326-1338.
53. Wender P.A., Cribbs C.M. Computer assisted molecular design related to protein kinase C receptor. Adv. Med. Chem. 1:1992;1-53.
54. Zhang G.G., Kazanietz M.G., Blumberg P.M., Hurley J.H. Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Cell. 81:1995;917-924.